Argatroban Stroke Treatment - A Pilot Safety Study
A Pilot Study To Determine The Safety Of Argatroban Injection In Combination With Tissue Plasmingen Activator (TPA) In Patients With Acute Ischemic Stroke
Sponsor: The University of Texas Health Science Center, Houston
A PHASE1/PHASE2 clinical study on Ischemic Stroke, this trial is completed. The trial is conducted by The University of Texas Health Science Center, Houston and has accumulated 9 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1_PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Completed PHASE1_PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
Feb 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- The University of Texas Health Science Center, Houston
For direct contact, visit the study record on ClinicalTrials.gov .